ClinicalTrials.gg

Program

nuzefatide pevedotin

Also written as “BT5528”, “nuzefatide pevedotin (BT5528)” and “Nuzefatide pevedotin”.

Its studies are mostly in Ovarian Neoplasms · Pancreatic Neoplasms, led by BicycleTx.

Furthest: phase 2, since Nov 19, 20193 company-led studies, 3 open or runningNext primary completion: Dec 31, 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
BicycleTx33 open or runningphase 2since Nov 19, 2019Nov 19, 2019Dec 31, 2026phase 2 · NCT04180371

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 19, 2019First study: phase 2 study in Ovarian NeoplasmsFirst studyNCT04180371 · 288 enrolled · United States, Belgium, South Korea and more
  2. Feb 26, 2026Phase 2 study in Pancreatic NeoplasmsNCT07450859 · 39 planned · United States, South Korea
  3. Jun 26, 2026Phase 2 study in Advanced Solid TumorsNCT07681674 · 16 planned

Ahead

  1. Dec 31, 2026Primary completion: phase 2 study in Ovarian NeoplasmsNCT04180371
  2. Mar 2029Primary completion: phase 2 study in Pancreatic NeoplasmsNCT07450859
  3. May 30, 2030Primary completion: phase 2 study in Advanced Solid TumorsNCT07681674

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07681674Advanced Solid Tumors2Not yet recruitingMay 30, 203016
NCT07450859Pancreatic Neoplasms · United States, South Korea2RecruitingMar 202939
NCT04180371Ovarian Neoplasms · United States, Belgium, South Korea and more2Active, not recruitingDec 31, 2026288

How it is read

Names in the registry

  • “BT5528”, 1 entry
  • “nuzefatide pevedotin (BT5528)”, 1 entry
  • “Nuzefatide pevedotin”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.